Hims & Hers Falls 14% After It Pulls Pulls Copycat Wegovy Pill—Novo Nordisk Up 8%
Faced with legal action, Hims and Hers walked back on its plans to launch the cheaper drug in an announcement Saturday. The company said: “Since launching the compounded semaglutide pill on our platform, we've had constructive conversations with stakeholders across the industry.
Novo Nordisk shares rise as Hims abandons $49 weight-loss pill
Novo Nordisk's Frankfurt-listed shares rose 4.5% on Monday after telehealth firm Hims & Hers reversed its launch of a $49 compounded weight-loss pill over the weekend, following legal threats from Novo and the U.S. Food and Drug Administration.
Hims & Hers pulls copycat weight-loss pill after threats of legal action
Hims & Hers on Saturday said it would stop offering its copycat Wegovy weight-loss pill. The decision comes after Novo Nordisk, maker of Wegovy, and the U.S. Food and Drug Administration threatened legal action against the telehealth provider.
Hims & Hers to stop offering compounded semaglutide pill after FDA crackdown
Hims & Hers said in a statement on Saturday that it will stop offering access to the compounded semaglutide pill after the U.S. Food and Drug Administration said it would take action against the telehealth provider for its $49 weight-loss pill.
FDA and HHS Hammer Hims & Hers In Compounded Drug Crackdown
Hims & Hers ( NYSE:HIMS ) shares are plunging 16% in after-hours trading following coordinated moves by two federal agencies against its compounded weight-loss drugs.
Hims & Hers stock nears one-year low amid battle over compounded Wegovy pill
Hims & Hers also said it's selling a cancer-detection test that's featured in its Super Bowl ad, which plays like a commentary on the wealthy's access to better healthcare.
Hims & Hers Strengthens Platform-Led Digital Healthcare Model
HIMS is scaling a platform-led digital healthcare model with Labs, AI and YourBio Health, integrating diagnostics, data and care into one ecosystem.
Hims & Hers falls 8% after Novo's legal threat. Here's the latest
Online telehealth company Hims & Hers stock fell Friday after Novo Nordisk said its newly announced Wegovy pill copy was illegal and that it would take legal action. Hims is launching its pill for as little as $49, significantly lower than the $149 Novo sells the branded pill for.
Novo Nordisk stock climbs out of hole on FDA chief's threat to block Hims and Hers pill
Novo Nordisk shares rallied on Friday in what's still been a painful week as the Food and Drug Administration may weigh in on the side of the Danish drugmaker in its dispute over a copycat drug.
Hims & Hers' $49 weight-loss pill jolts everyone, except its stock
Hims & Hers sent a shockwave through the pharmaceutical industry on Thursday with its announcement of a weight-loss pill with a $49-a-month introductory price. Its shares ended down anyway.
Hims & Hers Launches New Pill That Sends Shockwaves Across Weight-Loss Drugmakers' Stocks
A new pill from Hims & Hers Health is rattling shares of leading weight-loss drugmakers.
Hims & Hers launch of compounded $49 Wegovy pill pummels Novo Nordisk's shares
The compounded pill is less expensive than the oral version of Wegovy, which costs $149 to get started.
